Escient Pharmaceuticals
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
10578 Science Center Dr Ste 250, San Die...Phone Number
(858) 617-8220Website
www.escientpharma.comRevenue
$13.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Escient Pharmaceuticals
Escient Pharmaceuticals is a clinical-stage biotechnology company founded in 2018 and based in San Diego, California. The company specializes in research and development of innovative drugs targeting Mas-Related G Protein-Coupled Receptors (MRGPRs). Escient focuses on creating first-in-class therapeutics to address unmet medical needs across various therapeutic indications. The company utilizes a specialized platform technology for GPCR drug discovery and development, working to advance treatments for serious medical conditions. Escient Pharmaceuticals operates primarily in the research and development sector within the pharmaceutical industry, with multiple locations across North America.Explore more
Escient Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Escient Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Escient Pharmaceuticals recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Escient Pharmaceuticals has new funding data
Click to see if Escient Pharmaceuticals had a recent Job posting/layoffs
Escient Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Escient Pharmaceuticals
Check out if Escient Pharmaceuticals is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Escient Pharmaceuticals launches new products
Check if Escient Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Escient Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Escient Pharmaceuticals
Compare insights from companies similar to Escient Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Escient Pharmaceuticals
$13.3M
11-50
Private
$120M
2018
EC
Emma-Louise CrosbyChief Financial Officer & Company Secretary
Company Profile Activity
Activity Insights
Escient Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Escient Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Escient Pharmaceuticals.
Escient Pharmaceuticals financials insights
Gather financial insights about Escient Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series C
$120M
Escient Pharmaceuticals Tech Stack
A closer look at the technologies used by Escient Pharmaceuticals
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions
Open Position
Open Position
Open Position
Open Position
Escient Pharmaceuticals News & Media
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
WILMINGTON, Del. & SAN DIEGO--(BUSINESS WIRE)---- $INCY--Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR AntagonistsEscient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Atopic Dermatitis
SAN DIEGO--(BUSINESS WIRE)--Escient Pharmaceuticals, a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders, today announced that the first subject has been dosed in EASE, a Phase 2a clinical proof-of-concept study of EP262 in subjects with atopic dermatitis (AD). By blocking activation of MRGPRX2 and degranulation of mast cells, EP262 has the potential to effectively treat multiple mast cell mediated diseases with an initial foSimulocity Announces New Virtual Conference Center for Escient Pharmaceuticals
ORLANDO, FLORIDA, UNITED STATES, November 17, 2023 /EINPresswire.com/ -- Simulocity, a leading provider of innovative business solutions, is pleased to announce that they will be introducing a new technology as part of their partnership with Escient …Escient Pharmaceuticals Initiates Clinical Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonist, in Chronic Spontaneous Urticaria
SAN DIEGO--(BUSINESS WIRE)--Escient Pharmaceuticals, a clinical-stage drug development company advancing novel small molecule therapeutics for systemic neuro-immune disorders, today announced that the first subject has been dosed in CALM-CSU, a Phase 2 clinical proof-of-concept study of EP262 in subjects with chronic spontaneous urticaria (CSU). By blocking activation of MRGPRX2 and degranulation of mast cells, EP262 has the potential to effectively treat multiple mast cell mediated diseases wi
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Escient Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Escient Pharmaceuticals is a clinical-stage biotechnology company founded in 2018 and based in San Diego, California. The company specializes in research and development of innovative drugs targeting Mas-Related G Protein-Coupled Receptors (MRGPRs). Escient focuses on creating first-in-class therapeutics to address unmet medical needs across variou... Read More
